Inovio Pharmaceuticals, Inc.
(NASDAQ : INO)

( )
INO After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Medical Specialties
symbolcompany%chnglast%shortavg$volume
MDTMedtronic PLC
1.41%86.850.6%$503.03m
ISRGIntuitive Surgical, Inc.
1.90%517.782.4%$492.65m
TMOThermo Fisher Scientific Inc.
3.08%269.611.0%$454.54m
ABTAbbott Laboratories
1.77%78.110.8%$433.21m
BDXBecton, Dickinson and Company
2.17%237.551.1%$367.84m
ALGNAlign Technology, Inc.
-0.11%296.746.3%$348.20m
BSXBoston Scientific Corporation
4.23%36.941.1%$336.20m
SYKStryker Corporation
1.16%187.191.3%$276.11m
BAXBaxter International Inc.
-0.04%76.251.7%$241.63m
EWEdwards Lifesciences Corporation
-0.30%177.191.2%$224.13m
ABMDABIOMED, Inc.
-1.00%268.133.3%$214.45m
WATWaters Corporation
2.81%213.373.5%$149.73m
DXCMDexCom, Inc.
-0.59%118.128.4%$148.16m
ZBHZimmer Biomet Holdings, Inc.
0.20%124.701.7%$146.96m
TNDMTandem Diabetes Care, Inc.
0.52%60.164.0%$109.35m

Company Profile

Inovio Pharmaceuticals, Inc. is a late-stage biotechnology company, which engages in the discovery, development, and commercialization of DNA-based immunotherapies and vaccines. Its drug candidates include SynCon immunotherapies which helps break the immune system's tolerance of cancerous cells; and CELLECTRA delivery system which facilitates optimized cellular uptake of the SynCon immunotherapies. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.